The Y220C target mutation is a common oncogenic missense mutation, with a slightly lower mutation frequency compared to R249S and G245S located on the DNA binding surface.

Dolutegravir, a widely used antiretroviral drug, has shown excellent efficacy in treating HIV in adults. However, concerns have been raised about its potential neuropsychiatric side effects, which prompted the investigation into its impact on younger populations.

PI3Kα is a crucial lipid kinase and one of the most frequently mutated kinases in cancer. It consists of a heterodimer composed of the catalytic subunit p110α and the regulatory subunit p85α.

Lotilaner (Xdemvy), a small molecule drug that targets GluCls, was developed by Tarsus Pharma-ceuticals, Inc. and received FDA approval on July 24th, 2023 for the treatment of demodex blepharitis.

Glucose-dependent insulinotropic polypeptide (GIP) is one of two enteroinsular hormones, playing a crucial role in linking nutrient intake with whole-body metabolism.

FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.

This article will highlight the latest list of cancer pipeline drugs, specifically focussed on breast cancer pipeline drugs, pharmaceutical companies of researching breast cancer drugs, drug target of breast cancer, drug type of breast cancer and countries/locations of researching breast cancer drugs.

Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.

JAK3 is a narrow-spectrum member that only regulates γc cytokines, thus becoming an ideal potential target.

Selinexor, a small molecule drug targeting XPO1, is developed by Karyopharm Therapeutics, Inc.

The recent launch of the Clinical Trial Result Database on the Synapse Database resolves the problems of data comprehensiveness and selection.

Lanifibranor, a small-molecule drug targeting PPARα + PPARγ + PPARδ, was initially developed by AbbVie, Inc.